Wire flash
Eli Lilly raises full-year revenue outlook on strong diabetes and obesity drug sales, shares jump as much as 8%
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Eli Lilly shares jumped as much as 8% on Thursday after the Indianapolis-based pharmaceutical giant raised its full-year revenue outlook for the third time this year, driven by surging demand for its diabetes and obesity treatments. The company now expects full-year revenue of $91 billion to $92 billion, up from its previous estimate of $85 billion to $87 billion. Third-quarter revenue totaled $24.4 billion, topping the Wall Street consensus estimate of $22.5 billion. The results were primarily driven by Mounjaro, Lilly's diabetes drug, which brought in $10.7 billion in sales, while its weight-loss treatment Zepbound generated $5.35 billion. Lilly's GLP-1 business has benefited from tailwinds including the FDA's approval of Foundayo, the pill version of its weight-loss drug, earlier this year. The company is also developing next-generation weight-loss medicine retatrutide and plans to file for FDA approval in the first quarter of next year. The stock has risen 20% year-to-date after a drawdown in the first half of 2026.
Source report
By Ines Ferré, Senior Business Reporter Thu, October 29, 2026 at 6:55 AM PDT — 1 min read
What Happened
Eli Lilly (LLY) stock jumped as much as 8% on Thursday.
What's Behind the Move
Eli Lilly raised its full-year revenue outlook for the third time this year, buoyed by surging demand for its blockbuster diabetes and obesity treatments.
The Indianapolis-based pharmaceutical giant now expects full-year revenue of $91 billion to $92 billion, compared with its previous estimate of $85 billion to $87 billion.
Third-quarter revenue totaled $24.4 billion, topping the Wall Street consensus average estimate of $22.5 billion, according to Bloomberg data.
The results were primarily driven by:
- Mounjaro, Lilly's diabetes drug, which brought in $10.7 billion in sales
- Zepbound, the company's weight-loss treatment, which generated $5.35 billion
Stock Snapshot (LLY)
| Metric | Value | |---|---| | Close (Oct 30, 4:02 PM EDT) | 1,417.54 (+43.84, +3.19%) | | After hours (Oct 30, 7:59 PM EDT) | 1,414.51 (−3.03, −0.21%) |
What Else You Need to Know
Eli Lilly's GLP-1 business has been the growth engine of the drug company, benefiting from several tailwinds since the start of the year, including the FDA's approval of Foundayo — the pill version of its weight-loss drug — earlier this year.
The company is also developing next-generation weight-loss medicine retatrutide. It has clinical data in hand and plans to file for FDA approval in the first quarter of next year.
The stock, which suffered a drawdown in the first half of 2026, has risen 20% year-to-date, according to Yahoo Finance AlphaSpace data.
Ines Ferre is a Senior Business Reporter for Yahoo Finance covering the US stock market, publicly traded companies, and commodities. Follow her on X at @ines_ferre.
Click here for the latest trending stock tickers on the Yahoo Finance platform.
Source
"site:finance.yahoo.com" - Google NewsWestern
Part of this Story
Eli Lilly lifts 2026 revenue outlook to $91–$92 billion as Zepbound and Mounjaro sales surge